Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 3
2000 1
2001 1
2002 1
2003 4
2004 4
2005 1
2013 1
2014 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Immunotherapeutic perspective for bispecific antibodies.
van Spriel AB, van Ojik HH, van De Winkel JG. van Spriel AB, et al. Among authors: van ojik hh. Immunol Today. 2000 Aug;21(8):391-7. doi: 10.1016/s0167-5699(00)01659-5. Immunol Today. 2000. PMID: 10916142 Review.
IL-12: a promising adjuvant for cancer vaccination.
Portielje JE, Gratama JW, van Ojik HH, Stoter G, Kruit WH. Portielje JE, et al. Among authors: van ojik hh. Cancer Immunol Immunother. 2003 Mar;52(3):133-44. doi: 10.1007/s00262-002-0356-5. Epub 2003 Feb 12. Cancer Immunol Immunother. 2003. PMID: 12649742 Review.
No Effect of Vitamin C Administration on Neutrophil Recovery in Autologous Stem Cell Transplantation for Myeloma or Lymphoma: A Blinded, Randomized Placebo-Controlled Trial.
van Gorkom GNY, Boerenkamp LS, Gijsbers BLMG, van Ojik HH, Wodzig WKWH, Wieten L, Van Elssen CHMJ, Bos GMJ. van Gorkom GNY, et al. Among authors: van ojik hh. Nutrients. 2022 Nov 11;14(22):4784. doi: 10.3390/nu14224784. Nutrients. 2022. PMID: 36432471 Free PMC article. Clinical Trial.
FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection.
Ioan-Facsinay A, de Kimpe SJ, Hellwig SM, van Lent PL, Hofhuis FM, van Ojik HH, Sedlik C, da Silveira SA, Gerber J, de Jong YF, Roozendaal R, Aarden LA, van den Berg WB, Saito T, Mosser D, Amigorena S, Izui S, van Ommen GJ, van Vugt M, van de Winkel JG, Verbeek JS. Ioan-Facsinay A, et al. Among authors: van ojik hh. Immunity. 2002 Mar;16(3):391-402. doi: 10.1016/s1074-7613(02)00294-7. Immunity. 2002. PMID: 11911824 Free article.
Clinical evaluation of the bispecific antibody MDX-H210 (anti-Fc gamma RI x anti-HER-2/neu) in combination with granulocyte-colony-stimulating factor (filgrastim) for treatment of advanced breast cancer.
van Ojik HH, Repp R, Groenewegen G, Valerius T, van de Winkel JG. van Ojik HH, et al. Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):207-9. doi: 10.1007/s002620050434. Cancer Immunol Immunother. 1997. PMID: 9435875 Clinical Trial. No abstract available.
Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma.
Kruit WH, van Ojik HH, Brichard VG, Escudier B, Dorval T, Dréno B, Patel P, van Baren N, Avril MF, Piperno S, Khammari A, Stas M, Ritter G, Lethé B, Godelaine D, Brasseur F, Zhang Y, van der Bruggen P, Boon T, Eggermont AM, Marchand M. Kruit WH, et al. Among authors: van ojik hh. Int J Cancer. 2005 Nov 20;117(4):596-604. doi: 10.1002/ijc.21264. Int J Cancer. 2005. PMID: 15945101 Free article. Clinical Trial.
17 results